AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3145972 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT (3'-azido-3'-deoxythymidine)
Number of subjects: 38
Study 3145972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29956883 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (MEDI-551)
Number of subjects: 0
Study 29956883 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy donor skin)
Number of subjects: 0
Study 29956883 — intervention group
Group type: COMPARATOR
Intervention: Control (SLE patients)
Number of subjects: 0
Study 29956883 — intervention group
Group type: COMPARATOR
Intervention: Control (COPD patients)
Number of subjects: 0
Study 27135249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 231
Study 27135249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 231
Study 27135249 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (escitalopram)
Number of subjects: 231
Study 27135249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 27135249 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 231
Study 25491597 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 0.5 mg
Number of subjects: 99
Study 25491597 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone 100 mg
Number of subjects: 99
Study 25491597 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699 (doses > 1 mg)
Number of subjects: 99
Study 25491597 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI699
Number of subjects: 99
Study 25491597 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 99
Study 22406775 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/day for 5 days
Number of subjects: 50
Study 22406775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B capsules)
Number of subjects: 50
Study 20422062 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP asthma program
Number of subjects: 34
Study 20422062 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 19024255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-containing toothpaste
Number of subjects: 14
Study 19024255 — intervention group
Group type: COMPARATOR
Intervention: Regular toothpaste
Number of subjects: 14
Study 16613273 — intervention group
Group type: EXPERIMENTAL
Intervention: Liang's anti‐rheumatism and rheumatoid granule (LARG)
Number of subjects: 80
Study 16613273 — intervention group
Group type: COMPARATOR
Intervention: Wangbi granule
Number of subjects: 80
Study 11282811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25-75 mg, flexible dose)
Number of subjects: 44
Study 11282811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9547934 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day
Number of subjects: 0
Study 7507052 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1645
Study 3193368 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term speech spectrum display in time-swept mode with vibration amplitude encoding spectral amplitude
Number of subjects: 0
Study 3193368 — intervention group
Group type: COMPARATOR
Intervention: LPC-derived vocal tract shape display as a filled bar graph with number of active vibrators encoding cross sectional area
Number of subjects: 0
Study 31808721 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention for students in the very low word reading proficiency cluster
Number of subjects: 481
Study 31808721 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention for students in the near-adequate word reading proficiency cluster
Number of subjects: 481
Study 30807767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine concentrations at the study median of 8.0 μmol/L
Number of subjects: 1228
Study 30807767 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 1228
Study 30807767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine
Number of subjects: 1228
Study 28436538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24303415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intratympanic and systemic steroid therapy
Number of subjects: 77
Study 24303415 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy alone
Number of subjects: 77
Study 21179101 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 61
Study 21179101 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 61
Study 19258833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 19258833 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 16758164 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal ultrasound
Number of subjects: 45
Study 15110197 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous myocardial laser revascularization (PMLR) with optimal medical therapy (n = 40)
Number of subjects: 82
Study 15110197 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure with optimal medical therapy (n = 42)
Number of subjects: 82
Study 15110197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PMLR and sham)
Number of subjects: 82
Study 11951287 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 0
Study 9753851 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease patients
Number of subjects: 56
Study 9753851 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 56
Study 9753851 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with coronary heart disease
Number of subjects: 56
Study 9753851 — intervention group
Group type: COMPARATOR
Intervention: Males control subjects
Number of subjects: 56
Study 9753851 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with coronary heart disease
Number of subjects: 56
Study 9753851 — intervention group
Group type: COMPARATOR
Intervention: Females control subjects
Number of subjects: 56
Study 7924366 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 1000 mL i.v. Ringer's acetate solution during a 40‐min period
Number of subjects: 12
Study 7924366 — intervention group
Group type: COMPARATOR
Intervention: Control period (without infusion)
Number of subjects: 12
Study 2912881 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atlanto-occipital fusion
Number of subjects: 20
Study 2912881 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 20
Study 31418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone break
Number of subjects: 414
Study 31418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger computer screen break
Number of subjects: 414
Study 31418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper break
Number of subjects: 414
Study 31418586 — intervention group
Group type: COMPARATOR
Intervention: No break
Number of subjects: 414
Study 28213121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10/20 mg QD (flexible)
Number of subjects: 602
Study 28213121 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 602
Study 28213121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 25229836 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy for 10 min
Number of subjects: 16
Study 25229836 — intervention group
Group type: COMPARATOR
Intervention: Active recovery (10 min of cycling and stretching)
Number of subjects: 16
Study 25229836 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (sitting for 10 min)
Number of subjects: 16
Study 23296826 — intervention group
Group type: EXPERIMENTAL
Intervention: 36% CP containing 50% RUP (50RUP)
Number of subjects: 239
Study 23296826 — intervention group
Group type: COMPARATOR
Intervention: 36% CP containing 36% RUP (36RUP)
Number of subjects: 239
Study 23296826 — intervention group
Group type: COMPARATOR
Intervention: corn silage-based growing diet in a drylot (DRYLOT)
Number of subjects: 239
Study 21695751 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-week exercise and self-management programme
Number of subjects: 48
Study 21695751 — intervention group
Group type: COMPARATOR
Intervention: Management under the general practitioner (GP)
Number of subjects: 48
Study 19139845 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated allograft
Number of subjects: 99
Study 19139845 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated allograft
Number of subjects: 99
Study 19139845 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 99
Study 17005074 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin and fosinopril
Number of subjects: 79
Study 17005074 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril alone
Number of subjects: 79
Study 15718041 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside administration to AD fibroblasts
Number of subjects: 0
Study 15718041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic beta-D-galactosidase activity in AD fibroblasts
Number of subjects: 0
Study 15718041 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of GM1 hydrolysis in AD fibroblasts
Number of subjects: 0
Study 15718041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysis rate of sphingolipids in AD fibroblasts
Number of subjects: 0
Study 12923023 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guided PCI
Number of subjects: 108
Study 12923023 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI (coronary angiography)
Number of subjects: 108
Study 9988392 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (1,000-1,500 IU IM) and FSH (75-100 IU SC) administered every alternate day until puberty and spermatogenesis achieved
Number of subjects: 14
Study 7551771 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size
Number of subjects: 0
Study 7551771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-group variability
Number of subjects: 0
Study 7551771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity (variety)
Number of subjects: 0
Study 7551771 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremity
Number of subjects: 0
Study 2121564 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg cyclandelate
Number of subjects: 10
Study 2121564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2121564 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cyclandelate twice daily for 14 days
Number of subjects: 10
Study 81844 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind food challenges
Number of subjects: 68
Study 81844 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with 1:20 weight/volume concentrations of food extracts by puncture technique
Number of subjects: 68
Study 81844 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing by puncture technique
Number of subjects: 68
Study 30859220 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 1921
Study 30859220 — intervention group
Group type: COMPARATOR
Intervention: Continued biventricular pacing
Number of subjects: 1921
Study 30859220 — intervention group
Group type: EXPERIMENTAL
Intervention: MPP programmed with wide LV electrode anatomical separation (MPP-AS)
Number of subjects: 1921
Study 30859220 — intervention group
Group type: EXPERIMENTAL
Intervention: MPP programmed with other settings (MPP-Other)
Number of subjects: 1921
Study 30859220 — intervention group
Group type: EXPERIMENTAL
Intervention: MPP-AS
Number of subjects: 1921
Study 28339526 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved glass marked with yellow tape at the midpoint
Number of subjects: 319
Study 28339526 — intervention group
Group type: COMPARATOR
Intervention: Unmarked curved glass
Number of subjects: 319
Study 28339526 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved glass marked with ¼, ½ and ¾ volume points
Number of subjects: 319
Study 25967070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single WEB
Number of subjects: 1678
Study 25967070 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated WEB
Number of subjects: 1678
Study 25967070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IVR
Number of subjects: 1678
Study 25967070 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated IVR
Number of subjects: 1678
Study 25967070 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1678
Study 21821725 — intervention group
Group type: EXPERIMENTAL
Intervention: Women First! intervention delivered over 6 weeks
Number of subjects: 74
Study 21821725 — intervention group
Group type: COMPARATOR
Intervention: Attention-only comparison group
Number of subjects: 74
Study 22103280 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (R)
Number of subjects: 71
Study 22103280 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal-on-metal hip arthroplasty (C)
Number of subjects: 71
Study 19369910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 181
Study 19369910 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 181
Study 16733865 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intravenously every 4 weeks for 3 times from the 28th week)
Number of subjects: 52
Study 16733865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same administration schedule as trial group)
Number of subjects: 52
Study 15663222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 150
Study 15663222 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 150
Study 15663222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11227239 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant Erythropoietin (r‐EPO) administered three times per week for four weeks
Number of subjects: 60
Study 11227239 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times per week for four weeks
Number of subjects: 60
Study 9355712 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (HD) for 4 hours using holofibre dialyser
Number of subjects: 30
Study 9355712 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) with Verapamil added intraperitoneally at a dose of 10 mg/L/cycle for 36 hours
Number of subjects: 30
Study 8467614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7-10 days followed by a gluten-free vegan diet for 3.5 months and a lactovegetarian diet for 9 months
Number of subjects: 34
Study 8467614 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 34
Study 3896279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (10‐30 mg three times a day, mean dose 69.4 mg per day)
Number of subjects: 31
Study 3896279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3896279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 31
Study 31512050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting Down Programme (CDP)
Number of subjects: 74
Study 31512050 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 74
Study 31512050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CDP and TAU
Number of subjects: 74
Study 30536161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral-rich solution
Number of subjects: 189
Study 30536161 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (0.9% NaCl)
Number of subjects: 189
Study 28082531 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg or 1200 mg
Number of subjects: 33
Study 28082531 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 24 mg
Number of subjects: 33
Study 28082531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25475879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulleted fact sheet summarizing key study information
Number of subjects: 144
Study 25475879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulleted fact sheet and feedback Q&A session
Number of subjects: 144
Study 25475879 — intervention group
Group type: COMPARATOR
Intervention: Standard consent procedures
Number of subjects: 144
Study 23370530 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care with free telepsychotherapy
Number of subjects: 179
Study 21317203 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy in step 1
Number of subjects: 13
Study 21317203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trastuzumab and letrozole in step 2
Number of subjects: 13
Study 19061882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 I.U., s.c.)
Number of subjects: 35
Study 19061882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 16403848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study 12638399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/Acetaminophen 325 mg (Percocet)
Number of subjects: 141
Study 12638399 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg (OxyContin)
Number of subjects: 141
Study 12638399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 11347285 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide/glycine cream
Number of subjects: 46
Study 11347285 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 46
Study 9572178 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 17
Study 9572178 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 17
Study 7723000 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3280483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet with increased dietary carbohydrate by 16% of total calories
Number of subjects: 8
Study 3280483 — intervention group
Group type: COMPARATOR
Intervention: Control population (not specified)
Number of subjects: 8
Study 31623934 — intervention group
Group type: EXPERIMENTAL
Intervention: PubMed Clinical Queries narrow search
Number of subjects: 3
Study 31623934 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Scholar
Number of subjects: 3
Study 31623934 — intervention group
Group type: COMPARATOR
Intervention: Google Web
Number of subjects: 3
Study 31623934 — intervention group
Group type: COMPARATOR
Intervention: PubMed
Number of subjects: 3
Study 31623934 — intervention group
Group type: COMPARATOR
Intervention: PubMed Clinical Queries broad search
Number of subjects: 3
Study 31722152 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg, orally, twice daily for 12 weeks
Number of subjects: 207
Study 31722152 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally, twice daily for 12 weeks
Number of subjects: 207
Study 31722152 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Number of subjects: 207
Study 31722152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 29130876 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 minutes of lab-based hands-off arthroscopy instruction using a cadaver and arthroscopy setup
Number of subjects: 0
Study 29130876 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 minutes of hands-on arthroscopy instruction in the lab on a cadaver knee
Number of subjects: 0
Study 29130876 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based lecture only
Number of subjects: 0
Study 29130876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on group
Number of subjects: 0
Study 25024102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenstar LS 900® biometry
Number of subjects: 200
Study 25024102 — intervention group
Group type: COMPARATOR
Intervention: Immersion A-scan US biometry
Number of subjects: 200
Study 25024102 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both devices
Number of subjects: 200
Study 24640656 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective polarized chromotherapy using blue and red light
Number of subjects: 0
Study 21740540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging (US) as a diagnostic triage tool
Number of subjects: 226
Study 21740540 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 226
Study 21740540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 226
Study 21740540 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 226
Study 21740540 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to initial treatment
Number of subjects: 226
Study 18639269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stenting
Number of subjects: 220
Study 18639269 — intervention group
Group type: COMPARATOR
Intervention: Nonstenting
Number of subjects: 220
Study 17032101 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline perceptions of personal control over illness
Number of subjects: 70
Study 17032101 — intervention group
Group type: COMPARATOR
Intervention: Control group (disease-free women)
Number of subjects: 70
Study 12949689 — intervention group
Group type: EXPERIMENTAL
Intervention: Proproten-100
Number of subjects: 0
Study 12949689 — intervention group
Group type: COMPARATOR
Intervention: Standard drugs
Number of subjects: 0
Study 10385494 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (4 or 10 mg/m2)
Number of subjects: 18
Study 10385494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8712392 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestions preoperatively and Robinson Crusoe story intraoperatively
Number of subjects: 60
Study 8712392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peter Pan story preoperatively and therapeutic suggestions intraoperatively
Number of subjects: 60
Study 8712392 — intervention group
Group type: EXPERIMENTAL
Intervention: Crusoe story preoperatively and Peter Pan story intraoperatively
Number of subjects: 60